IGF-1 Analogues: LR3 and DES Structural Variations and Receptor Binding in Research Models

Introduction Insulin-like Growth Factor-1 (IGF-1) is a central mediator of growth hormone (GH) signaling involved in tissue growth, cellular repair, metabolic function, and proliferation. Two widely examined analogues—IGF-1 LR3 and IGF-1 DES—help researchers study how structural modifications influence receptor activation, signaling duration, and tissue-specific responses. This article outlines IGF-1 biology followed by detailed sections on LR3 and DES, written strictly from a mechanistic, research-based perspective. What Is IGF 1? IGF-1 is a peptide hormone produced primarily in the liver in response to GH stimulation. It activates IGF-1 receptors (IGF-1R) and, to a lesser extent, insulin receptors (IR). Its downstream effects operate through the PI3K–AKT, MAPK, and mTOR pathways, influencing metabolism, survival, and growth. Because native IGF-1 is regulated by IGF binding proteins (IGFBPs), analogues offer a controlled way to study IGF-1R-specific activity. LR3 IGF-1: Structural Modification and Extended Activity IGF-1 LR3 features a 13-amino-acid N-terminal extension and a substitution of arginine at position 3. These modifications significantly reduce IGFBP binding, increasing receptor availability and extending activity. In research settings, LR3 allows long-duration IGF-1R stimulation and activation of PI3K-AKT, MAPK, and mTOR pathways under reduced IGFBP interference. IGF-1 DES (1–3 IGF-1): Truncated Analogue With Enhanced Local Activity IGF-1 DES lacks the first three amino acids of the IGF-1 sequence, further decreasing IGFBP binding. This analogue produces rapid and localized IGF-1R activation with a shorter activity period. Its strong local receptor affinity makes DES useful for studying tissue-specific IGF-1 effects and acute signaling responses. Mechanistic Comparison LR3 and DES share the same receptor target (IGF-1R) but differ in duration, IGFBP interaction, and tissue penetration. LR3 provides sustained receptor access and broad exposure, while DES offers intense, localized IGF-1R activation for shorter intervals. Both contribute complementary insights into IGF-1’s biological roles in controlled research environments. IGF-1R Signaling Overview IGF-1R engagement activates multiple intracellular pathways: PI3K → AKT (survival, glucose metabolism) RAS → MAPK (growth, differentiation) mTOR (protein synthesis, anabolic signaling) IRS-1/2 (insulin/IGF cross-talk) These pathways underpin IGF-1’s metabolic and growth-regulating effects in research models. Summary IGF‑1 analogues such as LR3 and DES help researchers examine how structural modifications influence receptor engagement, signaling intensity, and tissue specificity. LR3 provides sustained IGF‑1R signaling due to reduced IGFBP interaction, while DES offers rapid, localized receptor activation with a shorter half-life. Together, the analogues support comprehensive study of IGF‑1 pathway biology under different experimental designs. LR3 vs DES: Mechanistic Comparison (Research Only) | Parameter | IGF-1 LR3 | IGF-1 DES | | --- | --- | --- | | Structure | 13aa extension + Arg3 substitution | Truncated by 3 amino acids | | IGFBP Interaction | Reduced | Strongly reduced | | Receptor Activation | Sustained IGF-1R exposure | Rapid, localized IGF-1R activation | | Research Focus | Extended signaling duration | Short-duration, high-intensity signaling | | Half-Life | Longer activity window | Shorter activity window | Educational & Research Disclaimer This article is for educational and research purposes only. No medical advice or product claims are made. These compounds are not approved for human use and are intended solely for laboratory research. FAQ: What are IGF-1 LR3 and IGF-1 DES in research? IGF-1 LR3 and IGF-1 DES are synthetic analogues of the native growth-factor peptide Insulin‑like Growth Factor 1 (IGF-1). LR3 includes added amino acids and a substitution to reduce binding to IGF-binding proteins, while DES is a truncated form (missing the first three amino acids). Both are studied for their modified receptor-binding profiles, bioavailability, and signaling activity in experimental models. How do IGF-1 LR3 and IGF-1 DES function in laboratory studies? Research shows that LR3 has reduced affinity for IGF-binding proteins (IGFBPs) and a longer half-life, allowing increased receptor interaction and signaling effects compared to native IGF-1. Similarly, DES(1-3)IGF-1 lacks the first three amino acids, exhibits markedly reduced IGFBP binding and enhanced potency in specific systems. Are IGF-1 LR3 and IGF-1 DES considered therapeutic products? No. The versions described here are for research use only by The Peptide Company. They are not approved therapies, supplements, or consumer products and are intended for controlled laboratory and in-vitro experimentation only. What research applications involve IGF-1 LR3 and IGF-1 DES? These analogues are used in experimental studies investigating tissue-specific growth-factor effects, receptor-binding

For research use only. Not for human consumption.